Effectiveness of early budesonide intervention in Caucasian versus Asian patients with asthma: 3-Year results of the START study

Respirology

Volumn 11, Issue 6, 2006, Pages 767-775

  Tan, Wan C ^a   Lamm, Carl J ^b   Chen, Yu Zhi ^c   O'Byrne, Paul M ^d   Pedersen, Søren ^e   Busse, William W ^f   Ohlsson, Stefan V ^b   Ullman, Anders ^b   Andersson, Bertil ^b   Pauwels, Romain A ^g  

^a ST PAUL S HOSPITAL   (Canada)

^b ASTRAZENECA R AND D   (Sweden)

^c CAPITAL INSTITUTE OF PEDIATRICS   (China)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Asian; Asthma; Budesonide; Dry powder inhaler; Turbuhaler

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; LEUKOTRIENE RECEPTOR AFFECTING AGENT; PLACEBO;

ADULT; AGED; ARTICLE; ASIAN; ASTHMA; BRONCHITIS; BRONCHODILATATION; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EARLY DIAGNOSIS; FEVER; FORCED EXPIRATORY VOLUME; HUMAN; OUTCOMES RESEARCH; POPULATION RISK; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; SLEEP DISORDER; SYMPTOMATOLOGY; VIRUS INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FORCED EXPIRATORY VOLUME; GROWTH; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2; TREATMENT OUTCOME;

EID: 33750072895     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2006.00945.x     Document Type: Article

References (48)

1. Boulet L-P, Bélanger M, Carrier G. Airway responsiveness and bronchial-wall thickness in asthma with or without fixed airflow obstruction. Am. J. Respir. Crit. Care Med. 1995; 152: 865-71.
2. Kuwano K, Bosken CH, Paré PD, Bai TR, Wiggs BR, Hogg JC. Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1993; 148: 1220-5.
3. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N. Engl. J. Med. 1998; 339: 1194-200.
4. Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur. J. Respir. Dis. 1987; 70: 171-9.
5. Stewart AG, Tomlinson PR, Wilson J. Airway wall remodelling in asthma: a novel target for the development of anti-asthma drugs. Trends Pharmacol. Sci. 1993; 14: 275-9.
6. Azzawi M, Bradley B, Jeffery PK et al. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am. Rev. Respir. Dis. 1990; 142: 1407-13.
7. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am. Rev. Respir. Dis. 1993; 147: 697-704.
8. Djukanović R, Roche WR, Wilson JW et al. Mucosal inflammation in asthma. Am. Rev. Respir. Dis. 1990; 142: 434-57.
9. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma. Update on selected topics - 2002. J. Allergy Clin. Immunol. 2002; 110 (Suppl. 5): S141-219.
10. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Update 2004. NIH Publication No 02-3659.
11. 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N. Engl. J. Med. 1991; 325: 388-92.
12. Haahtela T, Järvinen M, Kava T et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N. Engl. J. Med. 1994; 331: 700-5.
13. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in non-steroid-dependent asthmatics. Am. Rev. Respir. Dis. 1990; 142: 832-6.
14. Kerstjens HAM, Brand PLP, Hughes MD et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N. Engl. J. Med. 1992; 327: 1413-19.
15. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med. 2000; 343: 332-6.
16. Van Essen-Zandvliet EE, Hughes MD, Waalkens HJ et al. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am. Rev. Respir. Dis. 1992; 146: 547-54.
17. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir. Med. 1994; 88: 373-81.
18. Pauwels RA, Pedersen S, Busse WW et al. on behalf of the START Investigators Group. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003; 361: 1071-6.
19. Selroos O, Löfroos A-B, Pietinalho A, Riska H. Asthma control and steroid doses 5 years after early or delayed introduction of inhaled corticosteroids in asthma: a real-life study. Respir. Med. 2004; 98: 254-62.
20. Osterman K, Carlholm M, Ekelund J et al. Effect of 1 year daily treatment with 400 μg budesonide (Pulmicort® Turbuhaler®) in newly diagnosed asthmatics. Eur. Respir. J. 1997; 10: 2210-15.
21. Sullivan SD, Buxton M, Andersson LF et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J. Allergy Clin. Immunol. 2003; 112: 1229-36.
22. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. 2000; 162: 75-80.
23. 2-adrenergic receptor on response to regular use of albuterol in asthma. Int. Arch. Allergy Immunol. 2001; 124: 183-6.
24. 2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin. Pharmacol. Ther. 1999; 65: 519-25.
25. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest 1997; 100: 3184-8.
26. 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997; 350: 995-9.
27. 2 adrenoceptor polymorphism. Thorax 2000; 55: 762-7.
28. Taylor DR, Kennedy MA. Beta-adrenergic receptor polymorphisms and drug responses in asthma. Pharmacogenomics 2002; 3: 173-84.
29. Xie H-G, Stein CM, Kim RB et al. Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics 1999; 9: 511-16.
30. Litonjua AA, Carey VJ, Weiss ST, Gold DR. Race, socioeconomic factors, and area of residence are associated with asthma prevalence. Pediatr. Pulmonol. 1999; 28: 394-401.
31. Simon PA, Zeng Z, Wold CM, Haddock W, Fielding JE. Prevalence of childhood asthma and associated morbidity in Los Angeles county: impacts of race/ethnicity and income. J. Asthma 2003; 40: 535-43.
32. Tan WC, Chan TB, Lim TK, Wong ECK. The efficacy of high dose inhaled budesonide in replacing oral corticosteroid in Asian patients with chronic asthma. Singapore Med. J. 1990; 31: 142-6.
33. Miyamoto T, Takahashi T, Nakajima S et al. on behalf of a Japanese Pulmicort Turbuhaler Study Group. Efficacy of budesonide Turbuhaler® compared with that of beclomethasone dipropionate pMDI in Japanese patients with moderately persistent asthma. Respirology 2001; 6: 27-35.
34. Pauwels RA, Busse WW, O'Byrne PM et al. The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study: rationale and design. Control. Clin. Trials 2001; 22: 405-19.
35. Brown H, Prescott R. Applied Mixed Models in Medicine. John Wiley and Sons Ltd, London, 1999.
36. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N. Engl. J. Med. 2000; 343: 1054-63.
37. McQuaid EL, Kopel SJ, Klein RB, Fritz GK. Medication adherence in pediatric asthma: reasoning, responsibility, and behavior. J. Pediatr. Psychol. 2003; 28: 323-33.
38. Degroodt EG, Quanjer PH, Wise ME, Vanzomeren BC. Changing relationships between stature and lung-Volumes during puberty. Respir. Physiol. 1986; 65: 139-53.
39. Degroodt EG, Vanpelt W, Borsboom GJJM, Quanjer PH, Vanzomeren BC. Growth of lung and thorax dimensions during the pubertal growth spurt. Eur. Respir. J. 1988; 1: 102-8.
40. Bisgaard H, Szefler SJ. Understanding mild persistent asthma in children: the next frontier. J. Allergy Clin. Immunol. 2005; 115: 708-13.
41. Rabe KF, Adachi M, Lai CKW et al. Worldwide severity and control of asthma in children and adults: the global Asthma Insights and Reality surveys. J. Allergy Clin. Immunol. 2004; 114: 40-7.
42. Lai CKW, De Guia TS, Kim Y-Y et al. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J. Allergy Clin. Immunol. 2003; 111: 263-8.
43. Adams RJ, Fuhlbrigge A, Guilbert T, Lozano P, Martinez F. Inadequate use of asthma medication in the Unted States: results of the Asthma in America national population survey. J. Allergy Clin. Immunol. 2002; 110: 58-64.
44. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N. Engl. J. Med. 2000; 343: 1064-9.
45. Doull IJM, Freezer NJ, Holgate ST. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone diproprionate. Am. J. Respir. Crit. Care Med. 1995; 151: 1715-19.
46. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol belcomethasone diproprionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993; 92: 64-77.
47. Allen DB, Bronsky EA, LaForce CF et al. Growth in asthmatic children treated with flucticasone proprionate. J. Pediatr. 1998; 132: 472-7.
48. Hall IP. Pharmacogenetics and ethnicity: more complexities of personalized prescribing. Am. J. Respir. Crit. Care Med. 2005; 171: 535-6.